New Risk • 5h
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €87.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (€87.5m market cap, or US$99.8m). Annonce • May 02
Arcticzymes Technologies Asa Strengthens Ip Platform with New Patent Grant Supporting Expansion into Rna Therapeutics Manufacturing ArcticZymes Technologies ASA announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company's strategic expansion into the rapidly growing RNA therapeutics manufacturing market. The newly granted patent strengthens ArcticZymes' proprietary technology platform with the introduction of a novel RNA restriction enzyme family focused on enabling analytical, process development and manufacturing workflows for therapeutic RNA production. The protection covers key application areas relevant to RNA processing, quality control and scalable manufacturing workflows. The global RNA therapeutics market continues to expand, driven by increasing clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel modalities. As programmes progress toward late-stage development and commercialisation, demand is rising for robust, scalable and IP-secure manufacturing technologies that can improve process efficiency, product quality and regulatory confidence. ArcticZymes expects the protected technology to strengthen ongoing business development discussions with prospective partners and customers active in RNA therapeutics manufacturing. ArcticZymes will continue investing in internal innovation, targeted IP creation and strategic collaborations to expand its presence in high-growth biomanufacturing segments. ArcticZymes believes RNA therapeutics represents a significant long-term growth opportunity and remains committed to building a differentiated portfolio of enabling technologies to serve this expanding market. Annonce • Dec 20
ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026 ArcticZymes Technologies ASA, Annual General Meeting, May 28, 2026. Annonce • Dec 09
ArcticZymes Technologies ASA Expands San HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers ArcticZymes Technologies introduced two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector. The new SAN HQ ELISA Senso Plus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as a reusable format, reduced assay execution times, and lower costs make it an invaluable tool for streamlining biomanufacturing operations. Complementing SensoPlus, the new SAN HQ GMP neo delivers a GMP-compliant version of ArcticZymes' widely utilized SAN HQ Triton FREE. This product reflects ArcticZymes' commitment to expanding its portfolio of high-performance nucleases, providing biomanufacturers the flexibility to select solutions tailored to their unique production needs. By adding GMP variants to its portfolio, ArcticZymes is proactively addressing the increasingly stringent regulatory requirements of the biomanufacturing industry, enabling partners to achieve compliance with global standards while optimizing their production processes. Annonce • Dec 04
ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025 ArcticZymes Technologies ASA, Annual General Meeting, May 27, 2025. Reported Earnings • Nov 07
Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.12 profit in 3Q 2023) Third quarter 2024 results: kr0.03 loss per share (down from kr0.12 profit in 3Q 2023). Revenue: kr24.1m (down 23% from 3Q 2023). Net loss: kr1.56m (down 126% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 51% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €1.15, the stock trades at a forward P/E ratio of 32x. Average trailing P/E is 24x in the Biotechs industry in Europe. Total loss to shareholders of 87% over the past three years. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €1.38, the stock trades at a forward P/E ratio of 34x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total loss to shareholders of 84% over the past three years. New Risk • Aug 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €88.4m (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (€88.4m market cap, or US$98.9m). New Risk • Aug 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: kr0.05 (vs kr0.11 in 2Q 2023) Second quarter 2024 results: EPS: kr0.05 (down from kr0.11 in 2Q 2023). Revenue: kr27.5m (down 2.4% from 2Q 2023). Net income: kr2.67m (down 52% from 2Q 2023). Profit margin: 9.7% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 40% per year, which means it has not declined as severely as earnings. Annonce • Jul 31
ArcticZymes Technologies ASA Announces the Appointment of Frank Mathias as Chairman of the Board of Directors Oxford Biomedica plc announced that Dr. Frank Mathias, Chief Executive Officer, has been appointed as Chairman of the Board of Directors of ArcticZymes Technologies ASA. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €2.21, the stock trades at a forward P/E ratio of 58x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.30 per share. New Risk • May 17
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 28% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (28% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin). Board Change • May 15
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Jane Theaker was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • May 14
ArcticZymes Technologies ASA Announces Board Resignations ArcticZymes Technologies ASA announced changes to its governance structure. The Election committee has proposed changes to the Board to guide and strengthen the strategic and commercial development of the company. Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately. During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating ArcticZymes into a globally profitable player in the life science tools sector. Her leadership laid a robust foundation for long-term growth, for which the Election committee extends its sincere appreciation. Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The committee acknowledges Mrs. Theaker's valuable contributions and thanks her for her service. Reported Earnings • May 09
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr30.0m (down 3.8% from 1Q 2023). Net income: kr3.17m (down 37% from 1Q 2023). Profit margin: 11% (down from 16% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings. Annonce • Apr 02
ArcticZymes Technologies ASA Announces Resignation of Edgar Koster as Board Member ArcticZymes Technologies ASA announced Board member Edgar Koster has informed the board that he will resign from the board with immediate effect for personal reasons. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment deteriorates as stock falls 33% After last week's 33% share price decline to €2.36, the stock trades at a forward P/E ratio of 72x. Average trailing P/E is 33x in the Biotechs industry in Europe. Total loss to shareholders of 61% over the past three years. New Risk • Feb 07
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (16% net profit margin). Reported Earnings • Feb 02
Full year 2023 earnings released: EPS: kr0.37 (vs kr0.65 in FY 2022) Full year 2023 results: EPS: kr0.37 (down from kr0.65 in FY 2022). Revenue: kr119.7m (down 13% from FY 2022). Net income: kr18.7m (down 43% from FY 2022). Profit margin: 16% (down from 24% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Annonce • Jan 30
Arcticzymes Technologies Asa Announces the Launch of Its First Gmp-Grade Product, San Hq ArcticZymes Technologies ASA announced the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). SAN HQ GMP from ArcticZymes offers a technically superior solution for the enzymatic removal of contaminating DNA from therapeutic products such as viral vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio to include a GMP-grade nuclease. ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced therapies sector. To streamline the supplier and material qualification process and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves as a superior solution. The inclusion of a US FDA DMF further facilitates regulatory submission. SAN HQ GMP not only offers a technically superior option for enzymatic applications and provides a more straightforward supplier qualification process for customers. By reducing risks and minimizing resource expenditure on external product qualification, the new SAN HQ GMP ensures that clients in the pharmaceutical industry can access the most cutting-edge solution without compromising on compliance. The new SAN HQ GMP will be available for ordering in the second half of February 2024. Annonce • Dec 21
ArcticZymes Technologies ASA Launches T7 RNA Polymerase ArcticZymes Technologies ASA announced the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is rapidly evolving, the T7 RNA Polymerase may support different research areas as well as being a key component in various molecular diagnostic applications. The T7 RNA Polymerase will be available for ordering during January 2024. Reported Earnings • Nov 03
Third quarter 2023 earnings released: EPS: kr0.12 (vs kr0.05 in 3Q 2022) Third quarter 2023 results: EPS: kr0.12 (up from kr0.05 in 3Q 2022). Revenue: kr31.2m (up 4.9% from 3Q 2022). Net income: kr6.06m (up 143% from 3Q 2022). Profit margin: 20% (up from 8.4% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. New Risk • Nov 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (12% net profit margin). Annonce • Sep 21
ArcticZymes Technologies ASA Announces DMF for SAN HQ GMP accepted by the US FDA ArcticZymes Technologies ASA announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers with a Letter of Authorization (LoA) for their product registrations with the US FDA upon request. AZT anticipates commercial launch of SAN HQ GMP in Fourth Quarter 2023. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.17 in 2Q 2022) Second quarter 2023 results: EPS: kr0.11 (down from kr0.17 in 2Q 2022). Revenue: kr28.2m (down 7.0% from 2Q 2022). Net income: kr5.60m (down 36% from 2Q 2022). Profit margin: 20% (down from 29% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Annonce • Jul 17
ArcticZymes Technologies ASA Appoints Michael Akoh as Chief Executive Officer, Will Commence His Position No Later Than 1 November 2023 ArcticZymes Technologies ASA announced the appointment of Michael Akoh as its new Chief Executive Officer. Michael is an accomplished business executive with strong leadership experience, and an established reputation in the life sciences sector. He has over 20+ years of international experience in general management, business development and commercialization within the biopharma industry, including senior roles at diagnostic, med tech and CRO companies. Michael holds a BSc. (Econ) and a MSc. in International Marketing and Management from the Copenhagen Business School. Michael will commence his position no later than 1 November 2023. Reported Earnings • May 05
First quarter 2023 earnings released: EPS: kr0.10 (vs kr0.41 in 1Q 2022) First quarter 2023 results: EPS: kr0.10 (down from kr0.41 in 1Q 2022). Revenue: kr31.2m (down 37% from 1Q 2022). Net income: kr5.04m (down 76% from 1Q 2022). Profit margin: 16% (down from 42% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Reported Earnings • Feb 04
Full year 2022 earnings released: EPS: kr0.65 (vs kr0.94 in FY 2021) Full year 2022 results: EPS: kr0.65 (down from kr0.94 in FY 2021). Revenue: kr137.7m (up 5.0% from FY 2021). Net income: kr33.1m (down 29% from FY 2021). Profit margin: 24% (down from 35% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment deteriorated over the past week After last week's 23% share price decline to €5.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 973% over the past three years. Annonce • Dec 21
ArcticZymes Technologies Launches SAN HQ 2.0 ELISA kit ArcticZymes Technologies announced the launch of the SAN HQ 2.0 ELISA kit. The SAN HQ 2.0 ELISA kit is intended as a natural companion product to already successful Salt Active Nuclease - SAN HQ 2.0. The new ELISA product is a classic sandwich immunoassay designed to detect and quantify the presence of the SAN HQ 2.0 nuclease at trace amounts. Customers working with bioprocessing workflows will be able to use SAN HQ 2.0 to remove contaminating nucleic acids, and then verify the removal of the nuclease using the SAN HQ 2.0 ELISA kit after downstream processing and purification. This is important as all processing agents, used during biomanufacturing processes leading to human therapeutic agents, are subject to tight controls with respect to residual amounts present in the final formulation. Quantification is critical, therefore the enzyme SAN HQ 2.0 and the new SAN HQ 2.0 ELISA kit are complementary products. The new ELISA kit will further accelerate the adoption of SAN HQ 2.0 in customers' bioprocessing workflows. The global biomanufacturing market has seen significant growth in recent years, in part due to a boom in cell and gene therapy development, and the high demand for vaccine manufacturing during the Coronavirus pandemic. Providing customers with more complete solutions, such as processing enzymes and corresponding immunoassay kits, will be an important driver to continued sales growth in the biomanufacturing business. Annonce • Dec 02
ArcticZymes Technologies ASA Appoints Darren Ellis as Chief Scientific Officer ArcticZymes Technologies has appointed Dr. Darren Ellis as its first Chief Scientific Officer. Dr. Ellis brings over 20 years of industrial R&D experience (from Solexa (now Illumina) and ThermoFisher Scientific) in leading and developing molecular research and In Vitro Diagnostic (IVD) applications, technologies and products. Furthermore, he has global expertise in Business-to-Business (B2B) application development, successfully helping commercial partners and customers to bring their technologies and product developments tomarket. Dr. Ellis joined the Company in March this year to lead the establishment of the Application Laboratory at Oslo Science Park and to recruit an experienced team of application scientists. The laboratory is operational and currently focusing on the development of workflow applications related to infectious disease testing. As CSO, Dr. Ellis will support the Company to strategically expand and optimize the Company´s innovation capabilities and efforts in Norway and internationally as the Company grows both organically and inorganically. He will lead an international and experienced scientific team with the ability to bring further cutting edge and high-value innovations to market, hence, elevating theinnovation pipeline to the next level. Board Change • Nov 16
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: kr0.05 (vs kr0.14 in 3Q 2021) Third quarter 2022 results: EPS: kr0.05 (down from kr0.14 in 3Q 2021). Revenue: kr29.7m (up 12% from 3Q 2021). Net income: kr2.49m (down 64% from 3Q 2021). Profit margin: 8.4% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 147% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Oct 25
ArcticZymes Technologies ASA Announces Resignation of Volker Wedershoven as Board Member ArcticZymes Technologies ASA announced its Board member Volker Wedershoven has informed the board that he will resign from the board with immediate effect for personal reasons. The remaining board complies with the requirements regarding board composition and will still constitute a quorum. Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: kr0.17 (vs kr0.09 in 2Q 2021) Second quarter 2022 results: EPS: kr0.17 (up from kr0.09 in 2Q 2021). Revenue: kr30.3m (up 35% from 2Q 2021). Net income: kr8.75m (up 86% from 2Q 2021). Profit margin: 29% (up from 21% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 27%, compared to a 11% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 158% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: kr0.41 (vs kr0.40 in 1Q 2021) First quarter 2022 results: EPS: kr0.41 (up from kr0.40 in 1Q 2021). Revenue: kr49.2m (up 20% from 1Q 2021). Net income: kr20.8m (up 7.5% from 1Q 2021). Profit margin: 42% (down from 47% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 23%, compared to a 43% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 170% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairperson Marie Roskrow is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Jan 28
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: kr0.92 (down from kr1.53 in FY 2020). Revenue: kr131.0m (up 34% from FY 2020). Net income: kr46.2m (down 37% from FY 2020). Profit margin: 35% (down from 75% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.8%. Over the next year, revenue is forecast to grow 20%, compared to a 68% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has increased by 175% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Jan 28
ArcticZymes Technologies ASA Provides Sales Guidance for the Year 2022 ArcticZymes Technologies ASA provided sales guidance for the year 2022. For the year, the company expects topline sales growth with an annual sales target of NOK 155 million. Annonce • Dec 22
ArcticZymes Technologies Launches New Products ArcticZymes technologies announced the launch of following new products: ArcticZymes R2DTM Ligase - Patent pending ligase with novel specificity enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme is an enabling tool for new technology development and is expected to have broad applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS), and gene/RNA synthesis applications for potential therapeutic applications. IsoPol® BST+ High Concentration Glycerol FREE - highly concentrated formulation of the DNA polymerase to support ongoing customer opportunities for utility in new NGS platform technologies and Point-of-Care diagnostic test developments. M-SAN HQ ELISAkit - The new ELISA immunoassay product is an essential support product for customers using the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. In combination with the M-SAN HQ enzyme, the new immunoassay product provides a complete solution for the critical elimination of DNA contamination during biomanufacturing. M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing process has been upscaled and transitioned to large-scale fermentation. This successful upscaling achieved greater than a 100-fold increase in fermentation yield. The upscaling was necessary to meet the expected increase in demand following the launch of the ELISA kit and ensure customers can receive large quantities of enzyme from a single production batch. The ArcticZymes R2DTM Ligase and M-SAN HQ products will be available in its warehouses during January 2022. The IsoPol® BST+ High Concentration Glycerol FREE product will be available during February 2022. Recent Insider Transactions • Dec 12
Chief Executive Officer recently sold €1.0m worth of stock On the 10th of December, Jethro Holter sold around 120k shares on-market at roughly €8.68 per share. This was the largest sale by an insider in the last 3 months. This was Jethro's only on-market trade for the last 12 months. Reported Earnings • Oct 30
Third quarter 2021 earnings released: EPS kr0.14 (vs kr0.19 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr26.4m (down 16% from 3Q 2020). Net income: kr6.89m (down 24% from 3Q 2020). Profit margin: 26% (down from 29% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has increased by 177% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS kr0.09 (vs kr0.44 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr22.4m (down 34% from 2Q 2020). Net income: kr4.70m (down 78% from 2Q 2020). Profit margin: 21% (down from 63% in 2Q 2020). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 25% share price decline to kr7.60, the stock trades at a forward P/E ratio of 80x. Average forward P/E is 22x in the Biotechs industry in Europe. Total returns to shareholders of 1,392% over the past three years. Annonce • Jun 30
ArcticZymes Technologies ASA Launches SAN HQ 2.0 ArcticZymes Technologies ASA announced the launch of the second generation of its SAN HQ enzyme. ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme has achieved significant penetration in the viral vector manufacturing space in the last 5 years. Viral vectors are used in therapeutic applications such as vaccines and gene therapies. SAN HQ treatment is used in the downstream purification of viral vectors to remove contaminating DNA. The second generation of the enzyme, SAN HQ 2.0, has been optimised for wider compatibility with downstream processes used in biomanufacturing. In particular, SAN HQ 2.0 offers improved resolution in several chromatographic techniques, thereby simplifying the separation of the nuclease from the target product post treatment. ArcticZymes anticipates that SAN HQ 2.0 will increase the Company's reach within the viral vector space and provide new opportunities in recombinant protein production. The product will be commercially available from late third quarter 2021. Recent Insider Transactions • May 20
Director recently sold €170k worth of stock On the 18th of May, Volker Wedershoven sold around 20k shares on-market at roughly €8.49 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improved over the past week After last week's 20% share price gain to kr9.66, the stock trades at a trailing P/E ratio of 54.8x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 1,509% over the past three years. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS kr0.40 (vs kr0.28 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr41.0m (up 15% from 1Q 2020). Net income: kr19.4m (up 41% from 1Q 2020). Profit margin: 47% (up from 39% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has increased by 146% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 03
New 90-day high: €8.10 The company is up 27% from its price of €6.38 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment deteriorated over the past week After last week's 18% share price decline to kr5.82, the stock is trading at a trailing P/E ratio of 38.5x, down from the previous P/E ratio of 47.1x. This compares to an average P/E of 41x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 767%. Reported Earnings • Jan 30
Full year 2020 earnings released: EPS kr1.75 (vs kr0.13 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: kr97.8m (up 16% from FY 2019). Net income: kr75.4m (up kr81.8m from FY 2019). Profit margin: 77% (up from net loss in FY 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has only increased by 98% per year, which means it is significantly lagging earnings growth. Annonce • Jan 26
ArcticZymes Technologies ASA to Report Q4, 2020 Results on Jan 28, 2021 ArcticZymes Technologies ASA announced that they will report Q4, 2020 results at 7:00 AM, Central European Standard Time on Jan 28, 2021 Is New 90 Day High Low • Jan 22
New 90-day high: €7.74 The company is up 31% from its price of €5.92 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 21% share price gain to kr7.02, the stock is trading at a trailing P/E ratio of 73.4x, up from the previous P/E ratio of 60.8x. This compares to an average P/E of 47x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 841%. Valuation Update With 7 Day Price Move • Nov 20
Market bids up stock over the past week After last week's 15% share price gain to kr6.68, the stock is trading at a trailing P/E ratio of 71.8x, up from the previous P/E ratio of 62.3x. This compares to an average P/E of 44x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 826%. Valuation Update With 7 Day Price Move • Nov 05
Market bids up stock over the past week After last week's 16% share price gain to kr5.64, the stock is trading at a trailing P/E ratio of 60x, up from the previous P/E ratio of 51.9x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 636%. Valuation Update With 7 Day Price Move • Oct 29
Market pulls back on stock over the past week After last week's 33% share price decline to kr4.89, the stock is trading at a trailing P/E ratio of 52.6x, down from the previous P/E ratio of 78.9x. This compares to an average P/E of 33x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 533%. Is New 90 Day High Low • Oct 07
New 90-day high: €6.60 The company is up 67% from its price of €3.96 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. Annonce • Sep 23
ArcticZymes Technologies ASA to Report Q3, 2020 Results on Oct 22, 2020 ArcticZymes Technologies ASA announced that they will report Q3, 2020 results on Oct 22, 2020 Annonce • Aug 14
ArcticZymes Technologies ASA to Report Q2, 2020 Results on Aug 19, 2020 ArcticZymes Technologies ASA announced that they will report Q2, 2020 results at 7:00 AM, Central European Standard Time on Aug 19, 2020